Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
The ruling Liberal Democratic Party’s (LDP) health panel on February 25 postponed the approval of a draft bill to revise the Health Insurance Act, citing concerns raised by some lawmakers over the design of the new cost-sharing framework for so-called…
To read the full story
Related Article
- MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
- LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
March 5, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
REGULATORY
- MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
- MHLW Seeks 13.9 Billion Yen to Boost Domestic Biosimilar Production
September 2, 2026
- Health Minister Mum on Legislation for Chuikyo Reform
September 2, 2026
- Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…